Vioxx Articles

Novartis Trileptal approvable in USA; firm building broad franchise in

30 September 1999

COX-2 inhibitors boost US drug sales

22 September 1999

COX-2 inhibitors: potential in colon cancer?

9 September 1999

Celebrex sales drive Monsanto earnings rise

29 July 1999

Strong sales at Merck & Co push profits up 12% to $1.48 billion

27 July 1999

Vioxx hot on the tails of Celecoxib

15 July 1999

Fast progress for Vioxx and Xenical in USA

5 July 1999

Pharma to see "platinum age in 4th-qtr 1999," due to blockbusters, Y2K

11 June 1999

Vioxx launched in first EU market as marketing battle hots up

10 June 1999

Early US Rx data for Merck & Co's Vioxx

9 June 1999

Merck & Co's Vioxx approved in USA; battle starts for COX-2 market

24 May 1999

Stock Commentary New York

13 May 1999

Stock Commentary Tokyo

6 May 1999

US pharmaceutical firms weigh in with strong sales and earnings growth

29 April 1999

Vioxx backed for US approval, as Celebrex gets hit by side-effect concerns

21 April 1999

US pharma firms winning marketing battle with 20 of global top 25 drugs by

7 April 1999

First launch of Merck's Vioxx in Mexico

29 March 1999

Stock Commentary Tokyo

29 March 1999

Vioxx could debut in Mexico this month

17 March 1999

Mobic's US prospects boosted by Abbott deal

11 March 1999

Merck & Co's Vioxx to get FDA review in April

4 March 1999

Future growth of the global pharmaceutical market evaluated by MSDW

23 February 1999

Merck disappointment as highly-touted antidepressant stalls

26 January 1999

Vioxx to mount strong challenge to Celebrex

14 January 1999

Celebrex clears FDA with launch scheduled for later this month

7 January 1999

New Evidence Supports Vioxx GI Safety

15 December 1998

Celebrex Recommended For US Approval

2 December 1998

Merck & Co In 2-For-1 Stock Split, First Since 1992

26 November 1998

Merck & Co Submits NDA for Vioxx

25 November 1998

US Insurers Ponder COX-2 Inhibitors

23 November 1998

Pivotal Studies Of Celebrex Unveiled At ACR

19 November 1998

Phase III Rofecoxib Data In Osteoarthritis

12 November 1998

Pfizer Aims For Top Slot After Millenium

10 November 1998

Goldman Sachs, MSDW Top II's 1998 Analysts List

10 November 1998

Studies Reveal Side Effect Burden With Fosamax

15 October 1998

Merck & Co's $300 Million Investment In Singapore

9 October 1998

Priority FDA Review For Searle's Celebra

25 August 1998

Viagra Phenomenon Set To Transform Pharma Industry

6 May 1998

Efficacy Shown With Merck's Vioxx

21 April 1998

Analysts Forecast Bright Outlook For US Majors

8 April 1998

Pfizer Licenses Searle's Celecoxib For Arthritis

24 February 1998

...Merck Confident It Can Hold Growth Rates

9 December 1997

Showing 401-442 of 442 articles

Go to beginningPreviousNextGo to end